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5-Aminolaevulinic acid (ALA) and its derivatives have been widely used in photodynamic therapy (PDT) as precursors of the 
photosensitizer, protoporphyrin IX (PpIX) in dermatology and urology. However, ALA–PDT is limited by the low 
bioavailability of ALA due to the fact that  ALA is poorly absorbed by cells by virtue of its zwitterionic nature at physiological 
pH. In order to improve the therapeutical effect and induce higher levels of PpIX, a series of ALA prodrugs were synthesized 
by the conjugation ALA to 3-hydroxypyridin-4-ones (HPO) iron chelator using an amino acid linkage via amide bonds. 
Pharmacokinetic studies indicated that one ALA–HPO conjugate significantly enhanced PpIX production in a range of tumor 
cell lines over above that caused by ALA alone or the co-administration of ALA and CP94 (1,2-diethyl-3-hydroxypyridin-4-
one). The intracellular porphyrin fluorescence levels showed good correlation with cellular photo-toxicity following light 
exposure, suggesting the potential application of the ALA–HPO conjugates in photodynamic therapy. 
 
1. Introduction 
Photodynamic therapy (PDT), based on the activation of 
exogenously applied or endogenously formed photosensitizers 
by visible light in the presence of molecular oxygen, is a 
promising treatment strategy for malignant and non-malignant 
lesions. Upon exposure to light, a photosensitizer generates 
singlet oxygen and/or free radicals, which oxidize cellular 
macromolecules, leading to the damage of a variety of 
subcellular substrates (such as phospholipid membranes, 
nucleic acids, and proteins), resulting in cell death.1-3ALA has 
been widely used in PDT for the treatment of actinic keratosis, 
squamous cell carcinoma, and Bowen’s disease, as well as 
cutaneous microbial infections such as acne, onychomycosis, 
and verrucae.4-8 ALA-induced PDT can also be used as a 
diagnostic tool for the visualization of precancerous changes in 
the mucosae by fluorescence spectroscopy.9,10 The main 
disadvantage of this therapy is that ALA is poorly absorbed by 
cells due to its high hydrophilicity, resulting in low 
bioavailability.11 In order to overcome this drawback, numerous 
effforts have been made, which are mainly centred on the 
development of ALA prodrugs with more favorable lipid 
solubility, such as esters,12,13 peptide derivatives.14,15 According 
to the action mechanism, ALA is metabolized via the heme 
biosynthesis pathway to produce the fluorescent 
photosensitizer protoporphyrin IX (PpIX).16,17 Ferrochelatase 
can catalyze the conversion of PpIX to light inactive heme, 
leading to a decrease in the therapeutical effect.18 Thus, the 
activity of ferrochelatase is a key factor that influences the 
accumulation of PpIX in the cell.19,20 Iron chelators can inhibit 
the activity of ferrochelatase by scavenging the intracellular 
labile iron pool. It has been demonstrated that ALA–PDT can be 
modulated in the presence of iron chelators such as EDTA,21 and 
desferioxamine.22-24 Several studies have also demonstrated 
that a combination of ALA and the membrane permeable iron 
chelator CP94 (1,2-diethyl-3-hydroxypyridin-4-one) in PDT is an 
effective technique to increase the efficacy of ALA-PDT within 
cells under both in vitro and in vivo conditions.25–28 Previously, 
we reported that ALA–HPO conjugates, in which the ALA moiety 
was linked to a HPO moiety via an ester bond, significantly 
enhanced PpIX formation in cells of the human breast 
adenocarcinoma (MDA-MB-468), in comparison with ALA alone 
or with a combination of ALA with deferiprone (1,2-dimethyl-3-
hydroxypyridin-4-one).29 In the present study, a range of novel 
ALA–HPO conjugates with reasonable lipophilicity were 
synthesized. In these molecules, ALA methyl ester was linked to 
phenylalanine or leucine via a peptide bond, while the HPO 
moiety was coupled to amino group on phenylalanine or 
leucine. The ALA–HPO conjugates are anticipated to be 
hydrolyzed by peptidases and esterases in the cytosol of tumor 
cells, liberating free ALA. The PpIX fluorescence induced by 
these ALA–HPO conjugates in a range of human tumor cell lines 
and their photo-toxicity have been investigated. 
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2. Results and discussion 
2.1. Chemistry 
The synthetic route of benzyl protected 3-hydroxypyridinones 
containing a carboxyl group (5) using maltol (1) as a starting 
material is presented in Scheme 1. The benzylation of maltol 
with benzyl chloride provided 2 in 86% yield. Condensation of 2 
with primary amines under basic conditions provided the 3-
hydroxypyridinone derivatives 3 in good yield (84–90%), which 
underwent selective oxidation of the methyl group at the 2-
position with selenium dioxide in acetic anhydride to give 
aldehyde 4 in 77-80% yield. Further oxidation of 4 in the 
presence of sodium hypochlorite and sulfonic acid provided the 
carboxylic acids 5 in reasonable yield (54-62%). Coupling 
reaction of 5 with L-amino acid esters was carried out in the 
presence of 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminiumhexafluorophosphate (HCTU), giving 
product 6 in moderate to good yield (68-81%) (Scheme 2). 
Compounds 6 were then hydrolyzed with lithium hydroxide to 
the corresponding carboxylic acids 7 in excellent yield (91-94%). 
Conjugation of 7 and methyl 5-aminolaevulinate was achieved 
in the presence of HCTU to give 8 (75-81% yield), which were 
subjected to hydrogenation to remove benzyl groups, 
generating ALA–HPO conjugates Z01-Z10 in excellent yield (93-
97%) (Scheme 2). All the compounds were fully characterized by 
1H NMR, 13C NMR, MS and HRMS. 
2.2. Fluorescence Pharmacokinetics 
In order to assess the efficacy of the structural designed ALA–
HPO conjugates Z01–Z10, at the onset of this study the ability 
of these ALA–HPO conjugates to generate the active, 
fluorescent photosensitizer PpIX was investigated by measuring 
the fluorescence intensity of the peak emission at 635 nm after 
incubation with a range of tumor cell lines, including A549 cell 
line (human lung carcinoma), MCF-7 cell lines (human breast 
adenocarcinoma), KB cell line (human mouth epidermal 
carcinoma cells), LNCap cell line (human prostate cells derived 
from metastatic site lymph node) and BPH-1 cell line (normal 
human prostate epithelial cells). 
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Scheme 1. Reagents and conditions：(a) BnCl, NaOH, CH3OH, 
reflux, 7-8h; (b) RNH2, NaOH, CH3OH/H2O, reflux, 2.5h; (c) SeO2, 
CH3COOH/(CH3CO)2O, reflux; (d) NH2SO3H, NaClO2, 
acetone/H2O. 
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Scheme 2.Reagents and conditions： (a) HCTU, Et3N, DMF, 
overnight; (b) i) LiOH, ii) Amberlite IR-120 (H form) ion exchange 
resin; (c) HCTU, Et3N, DMF, overnight; (d) CH3OH, Pd/C, 3h. 
 
Firstly, the efficacy of Z01–Z10 to produce PpIX in A549, KB, 
LNCap and BPH-1 cell lines at a concentration of 100 μM was 
assess by comparison with ALA (Fig. 1). It was found that after 
incubation for 24h, compounds Z02–Z10 at this concentration 
did not markedly enhance the synthesis of PpIX in these cells as 
compared to ALA, some of them even led to the production of 
less PpIX than ALA. However, compound Z01 was found to 
significantly increase PpIX production at 100 μM in A549, KB and 
LNCap cell lines, generating PpIX by 3.1, 2.9 and 4.0 times higher 
than that induced by ALA, respectively. For the BPH-1 cell line, 
the fluorescence intensity of PpIX induced by Z01 was only 1.5 
time larger than that induced by ALA, indicating that PpIX 
producing rate via heme biosynthesis pathway in tumor cell is 
much higher than that in normal cell. Significant differences of 
PpIX production was observed in these cell lines (P < 0.05). After 
incubation with Z01, the highest level of PpIX was detected in 
KB cell, the next in A549 cell. This difference could be attributed 
to the different peptidase and/or esterase bioavailability and 
activity in these cell lines, resulting in different releasing rates 
of free ALA. 
 
 
 
 
 
 
 
Fig. 1.PpIX production in A549, KB, LNCap and BPH-1 cell lines 
after incubation with 100 μM of ALA or ALA-HPO conjugates for 
24 h at 37 oC and humidified by 5% CO2. Bars represent standard 
deviation (n = 3). 
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Fig. 2. PpIX fluorescence intensities produced after incubation 
in tumor cell lines with 200 μM of ALA–HPO conjugates, co-
administration of ALA and CP94 (both 200 μM) for 3, 6 and 24 h 
at 37 oC and humidified by 5% CO2. (a) incubation with A549 cell 
line; (b) incubation with LNCap cell line. Bars represent standard 
deviation (n=3). *represents a significant difference (P < 0.05), 
**represents a very significant difference (P < 0.001). 
In this investigation, the efficacy of compounds Z01–Z10 to 
produce PpIX in A549, LNCap, KB and PBH-1 cell lines was 
compared with co-administration of ALA and CP94 by a time-
course study. In all the four cell lines, compounds Z02–Z10 were 
less efficient than the co-administration of ALA and CP94 to 
produce PpIX. However, Z01 was found to significantly enhance 
the PpIX production in comparison with the combination of ALA 
with CP94. It was found that PpIX fluorescence intensity profile 
of A549 cell line was similar to that of KB cell line at 200 μM at 
all incubation times. Thus, only the results of A549 cell line were 
presented (Fig. 2a). After incubation with the A549 cell line for 
3, 6 and 24h, PpIX fluorescence intensities generated by Z01 
(200 μM) was determined to be 27.7, 52.9 and 94.6 a.u., 
respectively, which were 1.6, 1.3 and 1.2 times higher than 
those induced by ALA in combination with CP94 (17.7, 42.1 and 
77.8 a.u. respectively). In the case of the LNCap cell line, after 
incubation for 3, 6 and 24h, PpIX fluorescence intensities 
generated by Z01 (200 μM) was determined to be 25.3, 47.1 and 
58.4 a.u., respectively; whereas those induced by ALA in 
combination with CP94 were 17.3, 31.3 and 46.0 a.u., 
respectively (Fig. 2b). The normal cell line PBH-1 produced a 
lower PpIX level than that presented for LNCap in Fig. 2b (data 
not shown). It is surprising that most of the newly synthesized 
ALA-HPO derivatives showed a similar efficacy in intracellular 
PpIX production to that of ALA with the exception of Z01. The 
lack of efficacy of generating PpIX from compounds Z02-Z10 
could partially be owing to their bioavailability within the cell 
lines under investigation. It was clearly noticeable some 
aggregation of those compounds on the surface of the 
incubated cells. Probably, the use of serum free media (in order 
to avoid releasing PpIX from the cells) containing the 
compounds would not promote the solubility of the lipophilic 
compounds, subsequently decreasing the intercellular 
availability. It was reported that the aggregation problem with 
the lipophilic compounds which led to reduction of uptake, was 
much less appreciable in full media with serum.30 The calculated 
partition coefficient (ClogP) value31 of Z01 was -1.23, while the 
values of Z02-Z10 range from -1.40 to 1.22, indicating that the 
lipophilicities of all these ALA-HPO conjugates were increased 
as compared to ALA (ClogP -3.91). However, it has been 
previously reported that increasing the lipophilicity of ALA 
derivatives to certain level could negatively influence the 
uptake of the compound.32,33 As this compound series were all 
expected to penetrate the cell membrane by a passive diffusion 
mechanism, it is reasonable to assume that the relatively poor 
performance of derivatives (Z02-Z10) in terms of PpIX 
production also reflects a slower rate of metabolism and a 
corresponding lower affinity for the peptidases and/or 
esterases involved in the release of ALA from the prodrug. The 
superior activity of Z01 to the other derivatives was probably 
due to its higher intercellular bioavailability and its more rapid 
metabolism of the prodrug. 
Owing to aggregation problem, we wished to evaluate the 
potential of Z01 in more cell lines. KB was known to be  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Kinetics of PpIX fluorescence in (a) Hela cell line; (b) MDA 
MB-435 cell line. Fluorescence measurements after incubation 
with variable concentration (50–250 μM) of ALA, ALA in 
combination with CP94, and Z01 for 5h at 37 oC humidified by 
5% CO2. Bars represent standard deviation (n=3). (P < 0.001 to 
0.05). 
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Fig. 4. Photo-toxicity after incubation with ALA or ALA+CP94, 
and ALA-HPO conjugates in a range of cell lines assessed by MTT 
assay. Cells were incubated with the compounds for 4 h and 
irradiated with blue light (2.5 J·cm-2). (a) compound 
concentration 200μM; (b) compound concentration 100μM. 
 
contaminated by Hela in all the stocks worldwide.34 Thus, Hela 
cell line (human cervical cells) and MDA-MB 435 cell line (breast 
cancer cells) were selected in the evaluation. As shown in Fig. 3, 
compound Z01 exhibited a dose dependent response of PpIX 
production at concentrations ranging between 50–250 μM in 
both Hela and MDA MB-435 cell lines. Again, Z01 was more 
efficient in PpIX production in these two cell lines than co-
administration of ALA and CP94, which was found to enhance 
PpIX levels when compared to ALA alone (P<0.001 to 0.05). 
 
2.3.  Cytotoxicity  
The photo-toxicity of prodrugs Z01-Z10 (cells incubated with the 
compounds and exposed to blue light) on the A549, KB, LNCap, 
BPH-1 and MCF-7 cell lines was investigated (Fig. 4). The 
percentage of cell survival with respect to the control cells 
(without compounds) was calculated for the investigated 
compounds. After the incubation of the tumor cells with 200 
μM of Z01, followed by the irradiation with blue light, efficient 
cell killing was observed. The survival percentages of A549, KB, 
LNCap and BPH-1 cell lines treated Z01 were determined to be 
16.3, 7.8, 13.5 and 12.4%, respectively; those data in the case of 
ALA were 54.7, 52.6, 61.9 and 70.8%, respectively (Fig. 4a). 
However, overall cytotoxicity of Z02-Z10 was not found to be 
significantly enhanced as compared to ALA (Fig. 4a). These  
 
 
Figure 5.Photo-toxicity after incubation with ALA, ALA+CP94 
and Z01 in tumor cell lines assessed by MTT assay. Cells were 
incubated with the compounds for 4 h and irradiated with blue 
light (2.5 J·cm-2).(a) Hela cell line; (b) MDAMB-435 cell line. 
 
results were in agreement with those obtained from PpIX 
fluorescence experiments. The comparison of cytotoxicity of 
Z01-Z10 with co-administration of ALA and CP94 was also 
investigated at both 100 μM (Fig. 4b) and 200 μM (data not 
shown). At a concentration of 100 μM, Z01 was found to be 
more efficient in cell killing than the combination of the ALA 
with CP94 (P < 0.05). The survival percentages of A549, MCF-7, 
LNCap and BPH-1 cell lines treated with Z01 were determined 
to be 14.7, 21.1, 26.3 and 75.1%, respectively; those data in the 
case of ALA combined with CP94 were 18.4, 26.7, 33.1 and 
81.9%, respectively (Fig. 4b). Thus, at this concentration, both 
Z01 and ALA in combination with CP94 were found to be much 
less toxic on normal cells than on tumor cells. At 100 μM, 
compounds Z02-Z10 were all found to be of low toxicity to the 
tested tumor cell lines.  
The photo-toxicity of the most active conjugate Z01 on 
additional two cell lines (Hela and MDA MB-435) in comparison 
with ALA, and ALA+CP94 over a range of concentrations 
between 50-250 μM is presented in Fig. 5. The cytotoxicity was 
dose dependent. It was found that Z01 exhibited the highest 
photo-toxicity, and ALA the lowest, on these two cell lines. 
Significant differences between the treatments were observed 
(P < 0.05). The survival percentages of Hela cell line treated with 
Z01, ALA and ALA+CP94 at 250 μM were determined to be 15.3, 
58.6 and 26.9% respectively. For MDA MB-435 cell line 
incubated with Z01 and ALA (250 μM), the survival percentages 
were 11.1, 61.4 and 28.9%, respectively. 
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The “dark” toxicity of the ALA-HPO conjugates Z01-Z10 (cells 
incubated with the compounds without light exposure) on 
A549, MCF-7, LNCap and BPH-1 cell lines as percentages of 
control (cells without compounds and without light exposure) 
was evaluated. The data indicated that there was no significant 
toxicity found for ALA or all the investigated compounds at 200 
μM after 4h incubation (data not shown). 
3. Experimental  
The general synthetic procedures and spectral data for 
allcompounds are given in the ESI.† The spectral data for the 
final compounds Z01-10 are given below. 
3.1. Spectral data for compounds Z01-10 
Z01. 1H NMR (DMSO-d6, 500MHz) δ 2.50 (t, J=6.5Hz, 2H, 
CH2COO), 2.70 (t, J=6.5Hz, 2H, COCH2), 2.87 and 3.17 (m, 2H, 
CH2), 3.54 (s, 3H, COOCH3), 3.58 (s, 3H, NCH3), 3.97-4.08(m, 2H, 
CH2CO), 4.87-4.92 (m, 1H, CH), 7.18-7.36 (m, 6H, Ph and buried 
C5-H in pyridinone), 8.14 (d, J=7.5Hz, 1H, C6-H in pyridinone), 
8.70 (t, J= 5.5Hz, 1H, NH), 9.51 (d, J=8.5Hz, 1H, NH).13C NMR 
(DMSO-d6, 125MHz) δ 27.1, 33.9, 37.5, 42.8, 48.4, 51.4, 53.9, 
111.7, 126.5, 128.2, 129.3, 136.3, 137.3, 138.9, 142.9, 158.9, 
161.7, 170.6, 172.6, 205.1. ESI-MS: m/z 444 ([M+H]+). HRMS-
ESI: calcd. for C22H26N3O7 444.1771 ([M+H]+), found 444.1762. 
Z02. 1HNMR (DMSO-d6, 500MHz) δ 1.13 (t, J=7.0Hz, 3H, CH3), 
2.50 (t, J=6.5Hz, 2H, CH2COO), 2.71(t, J=6.5Hz, 2H, COCH2), 2.87 
and 3.19 (m, 2H, CH2), 3.57 (s, 3H, COOCH3), 3.73 and 3.97 (m, 
2H, CH2CO), 4.02 (q, J= 7.0Hz, 2H, NCH2), 4.93 (m, 1H, CH), 7.20-
7.36 (m, 5H, Ph), 7.42 (d, J=7.0Hz, 1H, C5-H in pyridinone), 8.26 
(d, J=7.0Hz, 1H, C6-H in pyridinone), 8.72 (t, J=5.5Hz, 1H, NH), 
9.60 (d, J=8.5Hz, 1H, NH). 13C NMR (DMSO-d6, 125MHz) δ 16.3, 
27.1, 33.8, 37.5, 48.4, 51.4, 51.5, 54.1, 112.3, 126.5, 128.2, 
129.2, 136.3, 137.3, 137.6, 142.8, 158.9, 161.4, 170.6, 172.6, 
205.1. ESI-MS: m/z 458 ([M+H]+). HRMS-ESI: calcd. for 
C23H28N3O7 458.1927 ([M+H]+), found 458.1924. 
Z03. 1H NMR (DMSO-d6, 500MHz) δ 0.75 (t, J=7.5Hz, 3H, CH3), 
1.05 (m, 2H, CH2), 1.52 (m, 2H, CH2), 2.49 (t, J=6.5Hz, 2H, 
CH2COO), 2.70 (t, J=6.5Hz, 2H, COCH2), 2.87 and 3.17 (m, 2H, 
CH2), 3.57 (s, 3H, COOCH3), 3.69 and 4.06 (m, 2H, CH2CO), 4.01 
(t, J=5.5Hz, 2H, NCH2), 4.86 (m, 1H, CH), 7.19-7.39 (m, 6H, Ph 
and buried C5-H in pyridinone), 8.24 (d, J=7.0Hz, 1H, C6-H in 
pyridinone), 8.73 (t, J=5.5Hz, 1H, NH), 9.60 (d, J=8.0Hz, 1H, NH). 
13C NMR (125MHz, DMSO-d6) δ 13.2, 18.7, 27.1, 32.4, 33.8, 37.3, 
48.4, 51.4, 54.3, 55.8, 111.9, 126.5, 128.2, 129.2, 135.9, 137.3, 
138.1, 143.1, 159.0, 161.7, 170.7, 172.6, 205.1. ESI-MS: m/z 486 
([M+H]+). HRMS-ESI: calcd. for C25H32N3O7 486.2240 ([M+H]+), 
found 486.2234. 
Z04. 1H NMR (DMSO-d6, 500MHz) δ 0.82 (t, J=7.0Hz, 3H, CH3), 
0.98-1.14 (m, 4H, CH2), 1.19 (m, 2H, CH2), 1.54 (m, 2H, CH2), 2.49 
(t, J=6.5Hz, 2H, CH2COO), 2.70 (t, J=6.5Hz, 2H, COCH2), 2.87 and 
3.17 (m, 2H, CH2), 3.57 (s, 3H, COOCH3), 3.67 and 4.06 (m, 2H, 
CH2CO), 4.00 (t, J=6.0Hz, 2H, NCH2), 4.87 (m, 1H, CH), 7.20-7.37 
(m, 5H, Ph), 7.43 (d, J=7.0Hz, 1H, C5-H in pyridinone), 8.26 (d, 
J=7.0Hz, 1H, C6-H in pyridinone), 8.74 (t, J=5.5Hz, 1H, NH), 9.61 
(d, J=8.0Hz, 1H, NH). 13C NMR (DMSO-d6, 125MHz) δ 13.7, 21.8, 
25.0, 27.1, 27.2, 30.4, 33.8, 37.4, 48.4, 51.3, 54.3, 56.2, 112.0 
,126.4, 128.1, 129.2, 136.2, 137.3, 138.1, 142.9, 158.9, 161.5, 
170.7, 172.6, 205.1. ESI-MS: m/z 514 ([M+H]+). HRMS-ESI: calcd. 
for C27H36N3O7 514.2553 ([M+H]+), found 514.2546. 
Z05. 1H NMR (DMSO-d6, 500MHz) δ 2.50 (t, J=6.5Hz, 2H, 
CH2COO), 2.71 (t, J= 5Hz, 2H, COCH2), 2.87 and 3.18 (m, 2H, CH2), 
3.15 (s, 3H, OCH3), 3.28-3.41 (m, 2H, OCH2), 3.58 (s, 3H, 
COOCH3), 3.91 and 4.20 (m, 2H, CH2CO), 4.01(t, J= 6.0Hz, 2H, 
NCH2), 4.88 (m, 1H, CH), 7.21-7.36 (m, 6H, Ph and buried C5-H 
in pyridinone), 8.03 (d, J=7.0Hz, 1H, C6-H in pyridinone), 8.71 (t, 
J=5.5Hz, 1H, NH), 9.62 (d, J=8.5Hz, 1H, NH).13C NMR (DMSO-d6, 
125MHz) δ 27.1, 33.8, 37.3, 48.4, 51.4, 54.2, 55.4, 58.1, 69.7, 
111.3, 126.5, 128.2, 129.1, 135.4, 137.3, 139.4, 143.2, 159.0, 
162.4, 170.7, 172.6, 205.1. ESI-MS: m/z 488 ([M+H]+). HRMS-
ESI: calcd. for C24H30N3O8 488.2033 ([M+H]+), found 488.2023. 
Z06. 1H NMR (DMSO-d6, 500MHz) δ 0.91 (d, J=6.5Hz, 6H, CH3), 
1.57 (m, 2H, CH2), 1.74 (m, 1H, CH), 2.49 (t, J=6.5Hz, 2H, 
CH2COO), 2.71 (t, J=6.5Hz, 2H, COCH2), 3.57 (s, 3H, COOCH3), 
3.91-4.05 (m, 5H, NCH3 and CH2 in NHCH2CO), 4.53 (q, J=7.5Hz, 
1H, CH), 7.40 (d, J=7.0Hz, 1H, C5-H in pyridinone), 8.25 (d, 
J=7.0Hz,1H, C6-H in pyridinone), 8.58 (t, J=5.5Hz, 1H, NH), 9.40 
(d, J=8.0Hz, 1H, NH). 13C NMR (DMSO-d6, 125MHz) δ 21.3, 22.9, 
24.2, 27.1, 33.9, 40.4, 43.4, 48.3, 51.3, 51.5, 111.8, 136.6, 138.9, 
142.9, 159.0, 161.5, 171.6, 172.6, 205.1. ESI-MS: m/z 410 
([M+H]+). HRMS-ESI: calcd. for C19H28N3O7 410.1927 ([M+H]+), 
found 410.1917. 
Z07. 1H NMR (DMSO-d6, 500MHz) δ 0.92 (d, J=6.5Hz, 6H, CH3), 
1.38 (t, J= 7.5Hz, 3H, CH3), 1.57 (m, 2H, CH2), 1.73 (m, 1H, CH), 
2.49 (m, 2H, CH2COO), 2.71 (m, 2H, COCH2), 3.57 (s, 3H, 
COOCH3), 3.92-4.04(m, 2H, NCH2), 4.19-4.34 (m, 2H, CH2CO), 
4.55 (q, J=7.5Hz, 1H, CH), 7.39 (d, J=6.5Hz, 1H, C5-H in 
pyridinone), 8.29 (d, J=6.5Hz, 1H, C6-H in pyridinone), 8.57 (t, 
J=5.5Hz, 1H, NH), 9.42 (d, J=8.0Hz, 1H, NH). 13C NMR (DMSO-d6, 
125MHz) δ 16.5, 21.3, 23.0, 24.2, 27.1, 33.8, 40.4, 48.3, 51.4, 
51.5, 51.7, 112.2, 136.0, 137.8, 142.9, 159.0, 161.8, 171.5, 
172.6, 205.1. ESI-MS: m/z 424 ([M+H]+). HRMS-ESI: calcd. for 
C20H30N3O7 424.2084 ([M+H]+), found 424.2077. 
Z08. 1H NMR (DMSO-d6, 500MHz) δ 0.84 (t, J=7.5Hz, 3H, CH3), 
0.91 (d, J=6.5Hz, 6H, CH3), 1.24 (m, 2H, CH2), 1.57 (m, 2H, CH2), 
1.74 (m, 3H, CH2CH), 2.49 (t, J=6.5Hz, 2H, CH2COO), 2.72 (t, 
J=6.5Hz, 2H, COCH2), 3.57 (s, 3H, COOCH3), 3.91-4.02 (m, 2H, 
NCH2), 4.15-4.32 (m, 2H, CH2CO), 4.54 (q, J=7.0Hz, 1H, CH), 7.43 
(d, J=7.0Hz, 1H, C5-H in pyridinone), 8.32 (d, J=7.0Hz, 1H, C6-H 
in pyridinone), 8.60 (t, J=6.0Hz, 1H, NH), 9.45 (d, J=8.0Hz, 1H, 
NH).13C NMR (DMSO-d6, 125MHz) δ 13.2, 18.9, 21.2, 22.9, 24.1, 
27.1, 32.7, 33.8, 40.4, 48.3, 51.3, 51.5, 56.1, 112.0, 136.3, 138.2, 
143.0, 158.9, 161.6, 171.5, 172.6, 205.0. ESI-MS: m/z 452 
([M+H]+). HRMS-ESI: calcd. for C22H34N3O7 452.2397 ([M+H]+), 
found 452.2392. 
Z09. 1H NMR(DMSO-d6, 500MHz) δ 0.84 (t, J=6.5Hz, 3H, CH3), 
0.91 (d, J=6.5Hz, 6H, CH3), 1.22 (m, 6H, CH2), 1.57 (m, 2H, CH2), 
1.70-1.80 (m, 3H, CH2CH), 2.49 (t, J=6.5Hz, 2H, CH2COO), 2.71 (t, 
J=6.5Hz, 2H, COCH2), 3.57 (s, 3H, COOCH3), 3.91-4.03(m, 2H, 
NCH2), 4.14-4.32 (m, 2H, CH2CO), 4.55 (q, J=7.0Hz, 1H, CH), 7.44 
(d, J=7.0Hz, 1H, C5-H in pyridinone), 8.32 (d, J=7.0Hz, 1H, C6-H 
in pyridinone), 8.60 (t, J=6.0Hz, 1H, NH), 9.46 (d, J=7.5Hz, 1H, 
NH). 13C NMR (DMSO-d6, 125MHz) δ 13.7, 21.3, 21.9, 22.9, 24.2, 
25.2, 27.1, 30.6, 30.7, 33.8, 40.4, 48.3, 51.3, 51.5, 56.3, 112.0, 
136.3, 138.2, 143.0, 158.9, 161.5, 171.5, 172.5, 205.0. ESI-MS: 
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m/z 480 ([M+H]+). HRMS-ESI: calcd. for C24H38N3O7 480.2710 
([M+H]+), found 480.2701. 
Z10. 1H NMR (DMSO-d6, 500MHz) δ 0.92 (d, J= 6.0Hz, 6H, CH3), 
1.59 (m, 2H, CH2), 1.76 (m, 1H, CH), 2.51 (t, J=6.5Hz, 2H, 
CH2COO), 2.73 (m, 2H, COCH2), 3.23 (s, 3H, OCH3), 3.58 (s, 3H, 
COOCH3), 3.60-3.73 (m, 2H, OCH2), 3.93-4.05 (m, 2H, NCH2), 
4.39 (m, 1H, CH), 4.50 (m, 2H, CH2CO), 7.34 (d, J=6.5Hz, 1H, C5-
H in pyridinone), 8.12 (d, J=6.5Hz, 1H, C6-H in pyridinone), 7.91 
(t, J=5.5Hz, 1H, NH), 8.81 (d, J=8.0Hz, 1H, NH). 13C NMR (DMSO-
d6, 125MHz) δ 21.2, 23.0, 24.2, 27.1, 33.8, 40.2, 48.3, 51.3, 51.7, 
55.5, 58.1, 70.0, 111.4, 135.4, 139.4, 143.2, 159.1, 162.7, 171.6, 
172.6, 205.1. ESI-MS: m/z 454 ([M+H]+). HRMS-ESI: calcd. for 
C21H32N3O8 454.2189 ([M+H]+), found 454.2182. 
3.2. Biological assay 
3.2.1. Cell Culture 
The biological evaluation for ALA, ALA in combination with CP94 
as a mixture and ten novel ALA-HPO conjugates were carried 
out in a range of human cell lines. A549 cell line (human lung 
carcinoma), MDA MB-435 and MCF-7 cell lines (human breast 
adenocarcinoma), and Hela cell line (human cervical cells) were 
cultured in Dulbecco's Modified Eagle Medium media (DMEM). 
Human mouth epidermal carcinoma cell (KB cell line) was 
cultured in Eagle’s minimum essential medium (EMEM). Human 
prostate cells derived from metastatic site lymph node (LNCap 
cell line) and normal human prostate epithelial cell (BPH-1 cell 
line) were both cultured in Roswell Park Memorial Institute 
(RPMI 1460). All types of media contained L-glutamine (20 μM) 
and phenol red, supplemented with 10% fetal bovine serum 
(FBS) and Gentamycine (500 units/mL; Life Technologies). They 
were standardized to give an iron concentration between 450 
and 600 μg/100 g. The cells were grown as monolayers in 
sterile, vented-capped, angle-necked cell culture flasks 
(Corning) and were maintained at 37 °C in a humidified 5% CO2 
incubator (IR Autoflow Water-Jacketed Incubator; Jencons 
Nuaire) until confluent. 
3.2.2. Fluorescence Pharmacokinetics  
Cells were seeded into gama-sterilised 96 well plates (Orange 
Scientific, Triple Red Laboratory Technologies) at a density of 
approximately 5×104 cells per well for 48 hours. After removing 
the culture medium, the wells were washed with PBS.  The cells 
were incubated with freshly prepared solutions of ALA and ALA-
HPO prodrugs: 100μL of serum-free medium containing 5% 
DMSO and varying prodrug concentrations was added to a 
designated series of wells. Each plate contained control wells 
with cells without prodrug for determination of the background 
reading, and reference wells containing cells incubated with the 
same ALA concentrations. For drug incubation, serum-free 
medium was used since serum is known to cause release of PpIX 
from cells, thus resulting in loss of the florescence signal. The 
fluorescence signal from each well was measured with a 
fluorescence spectrometer plate reader using 405 nm excitation 
and 635 nm emission wavelengths, with slit widths set to 10 nm 
and an internal 515 nm long-pass filter on the emission side. The 
spectral scans were recorded between 600 and 750 nm, thereby 
selectively identifying PpIX. The mean fluorescence intensity 
(expressed in arbitrary units) was calculated after subtraction of 
the control values. PpIX fluorescence intensities were recorded 
over periods of 3, 6, and 24 h with varied concentration of ALA 
prodrugs (50–250 μM). 
3.2.3. Photodynamic Treatment 
Cells were seeded into 96-well plates at a density of 
approximately 5×104 per well. Following incubation for 48h, the 
cells were washed with PBS and 100μL solutions containing 
each compound at varying concentrations (between 50μM–250 
μM) were added to their designated wells for 4h incubation 
periods. Each well plate contained three control wells without 
the compound and the compound at five different 
concentrations in triplicate. The plates were irradiated with a 
fluence of (5 min) using a blue lamp, which emits a uniform field. 
Peak output is 420 nm, which overlaps with the PpIX soret band. 
Immediately following irradiation, the medium was replaced 
and cells were incubated for further 18h. Cell cytotoxicity was 
determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay: The cells were 
incubated with the compounds for 4h, washed, and after 18h 
they were subjected to the MTT assay. Cells were incubated 
with medium containing MTT (1mg/mL dissolved in full media) 
for 2h. The insoluble end product (formazan derivatives) was 
dissolved in 100 μL DMSO after removing the medium. UV 
absorption was quantified at 490 nm using a 96-well plate 
reader (MR 700 Dynatech, Dynex). The mean cell survival was 
calculated for each prodrug at every concentration tested and 
expressed as a percentage of control (cells only without the 
compounds but irradiated) cell survival values. For 
determination of “dark” toxicity of the compounds, well plates 
were prepared in the same manner as above but without 
irradiation.  
4. Conclusions 
Although ALA is a useful therapeutical agent for PDT, it is 
important to improve its bioavailability when administered 
systemically and intravenously in order to overcome 
distribution problems. Incorporation of iron chelating agents to 
ALA prodrugs offers a promising way to enhance the cellular 
PpIX accumulation by inhibiting ferrochelatase. In the present 
study, a series of ALA–HPO conjugates have been synthesized. 
Among these ALA prodrugs, Z01 exhibited the highest efficiency 
in cellular PpIX accumulation in a range of cell lines. Z01 was 
also found to be the most effective in enhancement of tumor 
cell phototoxicity when compared to ALA and to a combination 
of ALA with CP94. It is necessary to extend these promising 
results in an in vivo setting in order to further evaluate the 
potential of these ALA–HPO conjugates. 
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